# Vertex Pharmaceuticals Inc / Ma (VRTX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/vertex-pharmaceuticals-inc-ma/ JSON: https://steadybase.io/company/vertex-pharmaceuticals-inc-ma.json Checked Nov 10, 2026. Latest filing read: Nov 3, 2026.

## Company

- Legal name: VERTEX PHARMACEUTICALS INC / MA
- Ticker: VRTX (Nasdaq)
- SEC CIK: 0000875320
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Boston, MA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: vrtx.com
- Investor relations: https://investors.vrtx.com/
- LinkedIn: https://www.linkedin.com/company/vertex-pharmaceuticals
- Next earnings date: Feb 1, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $12.0B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.html
- Operating income: $4.2B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.html
- Net income: $4.0B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.html
- SG&A: $1.8B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.html
- Employees: 6,400 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.html
- Shares outstanding: 253,537,674 as of Oct 31, 2026 (10-Q filed Nov 3, 2026). Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.html
- Auditor: Ernst & Young LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $12.0B | $4.2B | $4.0B | $1.8B |
| Dec 31, 2024 | $11.0B | -$232.9M | -$535.6M | $1.5B |
| Dec 31, 2023 | $9.9B | $3.8B | $3.6B | $1.1B |
| Dec 31, 2022 | $8.9B | $4.3B | $3.3B | $944.7M |
| Dec 31, 2021 | $7.6B | $2.8B | $2.3B | $840.1M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/vertex-pharmaceuticals-inc-ma.json

## Officers and directors

- Reshma Kewalramani, CEO & President. Source: Form 4 filed Mar 3, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/0000875320-26-000129-index.htm
- Charles F. Wagner, Executive Vice President and Chief Operating & Financial Officer (Principal Financial Officer). Source: 10-K filed Feb 13, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm
- Grunsven Jasper van, EVP, CP and NPPO. Source: Form 4 filed Sep 10, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000272/0000875320-26-000272-index.htm
- Kristen Ambrose, SVP & Chief Accounting Officer. LinkedIn: https://linkedin.com/in/kristenambrose. Source: Form 4 filed Sep 1, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000267/0000875320-26-000267-index.htm
- Amit Sachdev, EVP Chief Patient & Ext Af Off. Source: Form 4 filed Jul 23, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000251/0000875320-26-000251-index.htm
- Ourania Tatsis, EVP, Chief Reg. & Quality Off.. Source: Form 4 filed Jul 23, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000253/0000875320-26-000253-index.htm
- Duncan McKechnie, EVP, Chief Commercial Officer. LinkedIn: https://linkedin.com/in/duncan-mckechnie-0262932. Source: Form 4 filed Jul 7, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000243/0000875320-26-000243-index.htm
- Joy Liu, EVP and Chief Legal Officer. LinkedIn: https://linkedin.com/in/joy-j-liu. Source: Form 4 filed Jul 6, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000241/0000875320-26-000241-index.htm
- Carmen Bozic, EVP and CMO. Source: Form 4 filed Jun 30, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000239/0000875320-26-000239-index.htm
- Mark E. Bunnage, EVP, Chief Scientific Officer. LinkedIn: https://linkedin.com/in/mark-bunnage. Source: Form 4 filed May 19, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000226/0000875320-26-000226-index.htm
- Edward Morrow Atkinson III, EVP, Chief Technical Ops. Off.. Source: Form 4 filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000106/0000875320-26-000106-index.htm
- Jonathan Biller, EVP and Chief Legal Officer. Source: Form 4 filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000108/0000875320-26-000108-index.htm
- Kristen C. Ambrose, Senior Vice President and Chief Accounting Officer (Principal Accounting Officer). Source: 10-K filed Feb 13, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm
- David Altshuler, EVP, Chief Scientific Officer. Source: Form 4 filed Jan 26, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000010/0000875320-26-000010-index.htm
- Jeffrey M. Leiden, Executive Chairman. Source: Form 4 filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/875320/000124282526000002/0001242825-26-000002-index.htm
- Diana McKenzie, Board member (per proxy). Source: DEF 14A filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000153/vrtx-20260402.htm
- Lloyd Carney, Board member (per proxy). Source: DEF 14A filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000153/vrtx-20260402.htm
- Suketu Upadhyay, Board member (per proxy). Source: DEF 14A filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/875320/000087532026000153/vrtx-20260402.htm

## Recent 8-K events

- Nov 2, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/vrtx-20261102.htm
- Oct 20, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000278/vrtx-20261020.htm
- Sep 1, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000264/vrtx-20260827.htm
- Aug 3, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/vrtx-20260803.htm
- Jul 7, 2026: Item 1.01, Entry into a material definitive agreement; Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/d113650d8k.htm
- May 13, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000204/vrtx-20260513.htm
- May 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/vrtx-20260504.htm
- Apr 29, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000166/vrtx-20260428.htm
- Mar 31, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000147/vrtx-20260331.htm
- Feb 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/vrtx-20260212.htm

## Insider trades (Form 4)

- Jul 2, 2026: Ourania Tatsis (EVP, Chief Reg. & Quality Off.) sold 1,500 shares, about $787,485. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000245/0000875320-26-000245-index.htm
- Jul 2, 2026: Duncan McKechnie (EVP, Chief Commercial Officer) sold 1,541 shares, about $799,779. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000243/0000875320-26-000243-index.htm
- Jul 1, 2026: Joy Liu (EVP and Chief Legal Officer) sold 828 shares, about $416,244. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000241/0000875320-26-000241-index.htm
- Jun 26, 2026: Carmen Bozic (EVP and CMO) sold 596 shares, about $287,570. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000239/0000875320-26-000239-index.htm
- Jun 18, 2026: Carmen Bozic (EVP and CMO) sold 1,020 shares, about $471,413. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000237/0000875320-26-000237-index.htm
- Jun 15, 2026: Carmen Bozic (EVP and CMO) sold 4,062 shares, about $1.8M. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000235/0000875320-26-000235-index.htm
- Jun 5, 2026: Carmen Bozic (EVP and CMO) sold 1,745 shares, about $785,250. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000233/0000875320-26-000233-index.htm
- Jun 1, 2026: Joy Liu (EVP and Chief Legal Officer) sold 828 shares, about $364,245. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000230/0000875320-26-000230-index.htm
- May 29, 2026: Carmen Bozic (EVP and CMO) sold 1,974 shares, about $888,300. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000228/0000875320-26-000228-index.htm
- May 15, 2026: Mark E. Bunnage (EVP, Chief Scientific Officer) sold 33 shares, about $14,964. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000226/0000875320-26-000226-index.htm
- May 15, 2026: Carmen Bozic (EVP and CMO) sold 1,354 shares, about $613,971. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000225/0000875320-26-000225-index.htm
- May 12, 2026: Carmen Bozic (EVP and CMO) sold 6,988 shares, about $3.1M. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000222/0000875320-26-000222-index.htm
- May 4, 2026: Sangeeta N. Bhatia (Director) sold 318 shares, about $134,746. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000175/0000875320-26-000175-index.htm
- May 1, 2026: Joy Liu (EVP and Chief Legal Officer) sold 1,104 shares, about $469,222. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000183/0000875320-26-000183-index.htm
- Apr 1, 2026: Joy Liu (EVP and Chief Legal Officer) sold 978 shares, about $439,288. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000157/0000875320-26-000157-index.htm

## Latest filings

- 8-K filed Nov 2, 2026: https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/vrtx-20261102.htm
- 10-K filed Feb 13, 2026: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm
- 10-Q filed Nov 3, 2026: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm
- DEF 14A filed Apr 2, 2026: https://www.sec.gov/Archives/edgar/data/875320/000087532026000153/vrtx-20260402.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/